BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.38 Million EUR | 44.92% |
| 2022 | -1.29 Million EUR | -169.2% |
| 2021 | 2.01 Million EUR | 68.62% |
| 2020 | -4.91 Million EUR | 6.01% |
| 2019 | -5.71 Million EUR | -9.53% |
| 2018 | -5.11 Million EUR | 33.51% |
| 2017 | -7.58 Million EUR | 40.91% |
| 2016 | -12.63 Million EUR | -255.64% |
| 2015 | -3.45 Million EUR | 8.32% |
| 2014 | -3.93 Million EUR | -5.95% |
| 2013 | -3.71 Million EUR | 25.78% |
| 2012 | -5 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.13 Million EUR | -713.57% |
| 2024 Q1 | -1.03 Million EUR | -281.23% |
| 2024 Q2 | -1.3 Million EUR | 86.45% |
| 2023 Q1 | -1.11 Million EUR | -209.09% |
| 2023 Q4 | 570 Thousand EUR | 180.51% |
| 2023 FY | - EUR | 44.92% |
| 2023 Q3 | -708 Thousand EUR | -4.12% |
| 2023 Q2 | -680 Thousand EUR | 39.07% |
| 2022 Q2 | -213 Thousand EUR | 80.19% |
| 2022 FY | - EUR | -169.2% |
| 2022 Q4 | 1.02 Million EUR | 179.86% |
| 2022 Q3 | -1.28 Million EUR | -501.41% |
| 2022 Q1 | -1.07 Million EUR | -119.84% |
| 2021 Q1 | -2.12 Million EUR | 24.42% |
| 2021 FY | - EUR | 68.62% |
| 2021 Q2 | 3.29 Million EUR | 254.72% |
| 2021 Q4 | -489 Thousand EUR | 30.34% |
| 2021 Q3 | -702 Thousand EUR | -121.31% |
| 2020 Q4 | -2.81 Million EUR | -523.23% |
| 2020 Q1 | -1.18 Million EUR | 64.79% |
| 2020 Q3 | -452 Thousand EUR | 61.33% |
| 2020 Q2 | -1.16 Million EUR | 1.27% |
| 2020 FY | - EUR | 6.01% |
| 2019 FY | - EUR | -9.53% |
| 2019 Q4 | -3.36 Million EUR | -253.26% |
| 2019 Q3 | -952 Thousand EUR | 46.82% |
| 2019 Q1 | -212 Thousand EUR | -37.66% |
| 2019 Q2 | -1.79 Million EUR | -744.34% |
| 2018 Q2 | -1.95 Million EUR | -12.99% |
| 2018 FY | - EUR | 33.51% |
| 2018 Q4 | -154 Thousand EUR | 89.55% |
| 2018 Q3 | -1.47 Million EUR | 24.73% |
| 2018 Q1 | -1.73 Million EUR | -3.77% |
| 2017 Q3 | -1.32 Million EUR | -67.34% |
| 2017 Q1 | -3.92 Million EUR | 46.85% |
| 2017 Q2 | -793 Thousand EUR | 79.79% |
| 2017 FY | - EUR | 40.91% |
| 2017 Q4 | -1.66 Million EUR | -25.77% |
| 2016 Q4 | -7.38 Million EUR | -268.11% |
| 2016 FY | - EUR | -255.64% |
| 2016 Q3 | -2 Million EUR | 17.45% |
| 2016 Q2 | -2.42 Million EUR | -148.58% |
| 2016 Q1 | -977.12 Thousand EUR | -3.83% |
| 2015 Q1 | -214.37 Thousand EUR | 0.0% |
| 2015 FY | - EUR | 8.32% |
| 2015 Q2 | -1.17 Million EUR | -446.57% |
| 2015 Q3 | -1.28 Million EUR | -9.58% |
| 2015 Q4 | -941.06 Thousand EUR | 26.71% |
| 2014 FY | - EUR | -5.95% |
| 2013 FY | - EUR | 25.78% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 100.219% |
| CureVac N.V. | -234.09 Million EUR | 98.98% |
| Biotest Aktiengesellschaft | 179 Million EUR | 101.334% |
| Biotest Aktiengesellschaft | 179 Million EUR | 101.334% |
| Formycon AG | 81.05 Million EUR | 102.945% |
| Heidelberg Pharma AG | -18.7 Million EUR | 87.24% |
| Medigene AG | -14.58 Million EUR | 83.634% |